Wird geladen...

Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges

Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards “me too” drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta Pharm Sin B
Hauptverfasser: Basavaraj, S, Betageri, Guru V.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2014
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4590717/
https://ncbi.nlm.nih.gov/pubmed/26579359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2013.12.003
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!